Premenstrual syndrome (PMS) is often co-morbid with panic disorder (PD). Selective serotonin reuptake inhibitors when they manifest separately, but their co-occurrence often complicates the treatment. Our objectives were to evaluate the clinical picture of PMS, co-morbid with PD and the way it changes under 6-month SSRI treatment course. For that purpose, we conducted a longitudinal interventional study. We examined 30 women suffering premenstrual screening tool (PSST) and Mini International Neuropsychiatric Interview (M.I.N.I.6.0.), respectively. Before treatment initiation, irritability, mood lability, anxiety, breast tension and tenderness, changes in appetite, headaches, palpitations, and abdominal bloating were most common. The somatic symptoms were more than twice as common as the psychological. After 6 months of treatment, most of the symptoms mentioned above were still present but less severe. Forty per cent of the women recovered completely. It seems that in cases of comorbidity between PMS and PD, though somatic symptoms are more common, SSRIs are an effective option for managing both somatic and psychological symptoms.
Introduction
Studies that examine the parallel manifestation dysphoric disorder (PMDD) and panic disorder (PD) have found a high prevalence of PMS among patients PMDD retrospectively and use structured interviews for assessment of PD. According to their results, [1] [2] [3] . Prospective studies have document an even higher rate (16-25%) of concomitant expression of PMS and PD [4, 5] . Premenstrual exacerbation of PD has been systematically examined. A few investigations report that women with PD complain more frequently of premenstrual worsening of its symptoms, but these results were not replicated by prospective evaluation [6] [7] [8] . Also, yet another panic attacks but also mood changes during the premenstrual period [9] . Well-proved is also a vital link between PMDD and PD [10] [11] [12] [13] . It has been shown that most women with PMDD (50-60%) react with a heightened level of anxiety and panic attacks after being exposed to a provoking agent (lactate [14] , carbon dioxide [15] , are inclined to catastrophic interpretations of physical sensations and a propensity towards anxiety, characteristic of both disorders [10] .
Based on this data, the hypothesis arises that PMS consists of different subgroups, one of which is especially susceptible to PD and features.
This provoked our interest to clarify the clinical picture of PMS co-morbid with PD treatment with selective serotonin reuptake inhibitors (SSRIs).
Materials and Methods

Subject selection
We enrolled 30 women suffering from PMS and PD simultaneously. We evaluated the clinical characteristics, the symptoms' severity, the ratio of somatic to psychological symptoms, and the symptom change during SSRIs treatment. The sample was gathered in out-as well as inpatient conditions among women searching PD who were eligible to SSRI treatment for that reason. Diagnoses were based on the edition (ICD 10) using the Mini International Neuropsychiatric Interview (M.I.N.I.6.0.), as well as a standardized screening questionnaire for retrospective evaluation of premenstrual symptoms in the preceding 12 months. Inclusion criteria fertile age (18 to 50 years), regular menstrual cycle of 21 to 35 days duration. Exclusion criteria current or in the preceding 3 months lactation, any gynaecological condition or use of hormonal physiological cyclicality of female sex hormones.
The eligible patients were offered to participate in the study. Their condition was followed up twice (at third and sixth month) using the same questionnaire.
All participants signed written informed consent before initiating the study procedures. The study design was granted permission by the Diagnostic instruments M.I.N.I.6.0. is a brief psychiatric interview that was developed to aid diagnosing Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) and ICD 10 disorders. It has been validated against the structured clinical interview for DSM (SCID), Composite International Diagnostic Interview for ICD 10 (CIDI) and professional opinion of the expert panel [16] .
Premenstrual symptoms screening tool (PSST)
The questionnaire we used to evaluate the developed based on the PSST [17] . With the purpose of precise evaluation of somatic symptoms, we examined them separately. The been present for two weeks before menses during the previous twelve months (two months for the whichever question needed further evaluation as mild, moderate, or severe. The severity of PMS rating. Severe PMS corresponds to PMDD. selection of SSRI as an antidepressant class and were determined by a trained psychiatrist.
Statistical analysis
For data analyses, we used SPSS version 13.0. Besides descriptive and frequencies statistics, we run Kolmogorov-Smirnov and Shapiro-Wilk tests for testing the normality of distribution, followed by Wilcoxon Signed Ranks Test for
Results
We recruited 35 women altogether. Five of them dropped out because of inaccurate completion of the questionnaire, non-compliance and premature termination of medication intake, failure to show up at a follow-up visit. We analyzed and presented the data gathered from 30 women. The participants were aged between 23 and 43 years (mean 31.2±7.89). All of them escitalopram -9 women.
Before treatment, the most common psychological symptoms were irritability and changes in appetite (100.0%), followed by mood swings, anxiety, and fatigue (90.0%), changes in sleep pattern (86.7%), depressed mood (80%), apathy (76.7%), and lack of concentration (83.3%). Despondency, sweets craving were also equally distributed -73.3%. The most common severe symptoms were irritability (86.7%), anxiety (73.3%), and sweets craving (40%). Severe apathy was observed in none of the participants.
Among somatic symptoms, the most prevalent were tension, breast tenderness, weight gain, headaches, and palpitations (100%). Many of the subjects also suffered from muscle aches (93.3%), abdominal bloating (90%), shivering (86.7%), and joint aches (63.3%). Most commonly severely expressed were breast swelling and tenderness (70%), palpitations (60%), abdominal bloating (50%), and shivering (43.3%).
Most of the women experienced moderately severe PMS (56.7%) and the rest of them (43.3%) -severe PMS (Figure 1 ).
The clinical picture of PMS co-morbid with PD was dominated by somatic symptoms, which were more than twice (2.33) more prevalent than psychological ( Figure 2 ). Three months after initiation of SSRIs intake, the prevalence of the psychological symptoms remained unchanged. All patients experienced anxiety (100%), which in 20% of them was severely expressed. Commonly present were also mood swings, irritability, appetite changes (83.3%), sweets craving (73.3%), lack of concentration (73.2%), and fatigue (60%). Among the most prevalent somatic symptoms were breast tension and tenderness (96.7%), which was severe in 40% of the women, headaches and abdominal bloating (90%), palpitations (86.7%), muscle aches (73.3%), shivering, weight gain (66.7%).
Psychological to somatic symptoms ratio remained approximately the same compared to visit 1 (0.43) - Figure 2 .
At visit 3 (after 6 months of medication intake) most common of the psychological symptoms were irritability and anxiety (90%) (severe in 20% and 10% of them, respectively), mood swings (86.7%), changes in appetite (76.7%), sweets cravings (73.3%), lack of concentration (60%). Concerning somatic symptoms, nearly all participants still complained of breast tension and tenderness (83.3%), palpitations (73.3%), abdominal bloating (70%), shivering (56.7%).
The ratio of psychological to somatic symptoms was 1.14 (Figure 2) .
Three months after initiation of treatment with SSRIs, all psychological symptoms except ameliorated ( Table 1) . Somatic symptoms were slightly improved. Breast tension and Clinical characteristics o premenstrual syndrome ... tenderness remained the leading symptom, but its severity also decreased -from 70% to 40% of the participants. Generally, the prevalence was observed in the ratio of somatic to of the syndrome itself was also ameliorated -the cases of severe PMS decreased in number and in 16.7% of the participants were fully resolved.
After six months of treatment, all psychological symptoms were reduced in frequency and severity. Mood swings, anxiety, lack of concentration, fatigue, sleep changes 3, all somatic symptoms except weight gain 1). The prevalence of psychological and somatic symptoms became nearly equal.
In 40% of the participants, full resolution of PMS symptoms was accomplished and in another one-fourth of them only mild or moderate symptoms persisted. Compared to difference in respect to the syndrome severity with treatment was retained.
Discussion
The presented study was an attempt to clarify the clinical picture of PMS co-morbid with PD and to follow its response to the initiation of treatment with SSRIs. According to our results, the co-morbidity was related to the dominance of somatic symptoms. Moreover, the presence of PD was associated with the appearance of period. In the available literature, there is a lack of information on the typical presentation of PMS in cases of comorbidity with PD, so any kind of comparison to our results is not feasible until replication studies appear.
In our sample, 56.7% of the women suffered from moderately severe PMS and 43.3%from PMDD. We observed no cases of the mildly expressed syndrome, even though such cases were not intentionally excluded from the study. The summarized data from previous investigations on the distribution of PMDD points to a prevalence of around 8% [18] [19] [20] [21] , but it has not been evaluated in the presence of comorbidity with PD. In our opinion, the probable reason why our results on the prevalence of PMDD were so high is that our study sample consisted of women suffering from both disorders simultaneously.
In our sample, despite the comorbidity and greater severity of PMS (43.3% of the participants suffered PMDD), all psychological symptoms during the 6 months of treatment. Similar results were reported by Halbreich et al. (2006) [22] . They analyzed the data from clinical studies symptoms of PMS and found that SSRIs reliably improved the psychological symptoms anger, irritability, mood swings, tension, and depression in patients without psychiatric comorbidity. Our results corroborate their effectively ameliorate the severe psychological symptoms in cases of PMS co-morbid with PD. Regarding somatic symptoms at the end of the 6-month treatment period, the prevalence of all improved were breast tension and tenderness. The ratio of psychological to somatic symptoms gradually equalized, and at visit 3, it was 1.14. The prevalence of somatic symptoms decreased from 70% at visit 1 to 46.7% at visit 3, which highlights the effectiveness of SSRIs on somatic symptoms.
This data is comparable to what is known from some of a large number of randomised placebo-controlled studies on the effectiveness of SSRIs in the treatment of PMS. All of them emphasize the improvement in psychological symptoms (especially irritability) but also in somatic (breast tension and abdominal bloating) [23] [24] [25] [26] [27] [28] . Further evidence for a direct effect of SSRIs on somatic symptoms can be found when comparing intermittent versus continuous dose regimens. It seems that continuous intake (the regimen used in the presented study) is related to a reduction in somatic symptoms and intermittent intake -only with improvement in psychological ones [22] . This way, our results SSRIs on somatic symptoms of PMS. However, unlike previous research, our sample consisted of patients suffering from both PMS and PD [22] summarized that independent of the treatment regimen, psychological symptoms were reliably improved, while the effect of SSRIs on somatic do not corroborate such a conclusion, but a sensible improvement was observable in more than three months of treatment.
Closer to our results is the data from a metaanalysis by Dimmock et al. (2000) [29] . They claim that SSRIs are effective for both somatic and behavioral symptoms. But not all studies included in this meta-analysis assess the somatic symptoms systematically, so the conclusions based on them should be taken with caution.
were able to perform a detailed assessment of somatic symptoms and to show an improvement in them under SSRIs treatment. Once again, our results are based on a sample of PMS patients Criteria for the effectiveness of SSRIs treatment include also change in the severity of PMS. Before treatment initiation, 56.7% and 43.3% suffered moderate and severe PMS, respectively. At the end of the follow-up period, 40% of the patients were symptom-free, meaning the syndrome was resolved entirely. In 26.7% of them, there were only mild complaints, and in 33.3% -moderately severe. Cases of severe PMS were not registered.
The presented data gives us a reason to summarize that the effectiveness of SSRIs makes [30] [31] [32] , but our results also allow us to claim them further effective in cases of co-morbid PD.
Conclusions
The dominance of somatic symptoms characterizes the typical clinical picture of untreated PMS co-morbid with PD. A continuous regimen of SSRIs intake brings a gradual improvement in symptoms. Severe cases of PMS are resolved, and 40% of the patients are symptom-free. SSRIs are effective for psychological as well as somatic symptoms of PMS co-morbid with PD.
